Welcome to the Porton Newsroom
Porton at CPhI North America again
STRATEGIC EXPANSIONS FOR CUSTOMER-CENTRIC & GLOBAL SOLUTIONS
Porton 2023 ESG Report
Porton has always adhered to the mission and original intention ofenabling the public's early access to good medicines and firmly practiced the concept
Upcoming Porton Shows in Europe and the USA：Shaping Our Future Together
STRATEGIC EXPANSIONS FOR CUSTOMER-CENTRIC & GLOBAL SOLUTIONS
Porton Newsletter | Q1 2024 Recap
Porton PharmaTech (Slovenia)-B31 R&D Labs and Kilo lab Suites (non-GMP), expected to be completed in May 2024.
New Facilities Will Be Ready in Porton USA / J-STAR
Porton's Antibody and ADC GMP Pilot Manufactory Officially Operated
Porton Makes Debut at DCAT Week 2024 to Jointly Promote Industry Development
STRATEGIC EXPANSIONS FOR CUSTOMER-CENTRIC & GLOBAL SOLUTIONS
Join Our Founder and CEO @ DCAT Week
STRATEGIC EXPANSIONS FOR CUSTOMER-CENTRIC & GLOBAL SOLUTIONS
Porton Pharma Solutions Joined the SBTi to Drive Climate Action
Porton announces the opening of a new drug development facility adjacent to its existing API synthesis facility in New Jersey, USA.
(September 5, 2023 – CRANBURY, NJ)
Farewell to 2023, and WE are Sailing forward to 2024
Porton announces the opening of a new drug development facility adjacent to its existing API synthesis facility in New Jersey, USA.
(September 5, 2023 – CRANBURY, NJ)
The Pharma Crystallization Summit (PCS) is held annually to bring together developers of new medicines with crystallization challenges and the crystallization experts (solution providers) in the industry and academia.
Porton announces the opening of a new drug development facility adjacent to its existing API synthesis facility in New Jersey, USA.
(September 5, 2023 – CRANBURY, NJ)
